Pelvic organ prolapse and urinary incontinence are common conditions in women that significantly diminish quality of life. With roughly 225,000–280,000 women requiring surgery each year in the United States alone, societal costs are over a billion dollars annually (1). While repair with synthetic mesh products have become the surgical treatment of choice, these meshes require very little premarket testing because they are based on previously approved abdominal wall hernia products (510K devices). Thus, there is little scientific data on the efficacy of meshes for gynecological surgery. Moreover, with the recent FDA warning citing large numbers of unreported complications in patients, there is growing concern about the use of gynaecological mesh, especially for transvaginal placement (2). Thus, there is a need to examine the ex-vivo properties of these meshes and relate them to their in-vivo function and outcomes for gynecological applications.

This content is only available via PDF.
You do not currently have access to this content.